Niger J Clin Pract
-
Hearing loss, also termed as hearing impairment, is an ailment where hearing is impaired partially or fully. About one in eight people suffer from hearing loss worldwide. The main aim of this current systematic review was to analyze the clinical effectiveness of cochlear implant (CI) surgery in pediatric and adult patients. ⋯ In the performance of post CI outcomes in patients, the age is not a determinant factor. CI is an effective aid in communication and speech perception for a majority of people with mild to severe hearing loss. Further studies are needed with large databases, patient registries for long term follow up details, higher quality reporting, and longer duration to develop stronger evidence.
-
Docetaxel (DOC) is the main chemotherapeutic agent for the treatment of advanced metastatic prostate cancer. Docetaxel shows anticancer effects by preventing the depolymerization of microtubules in the cell, therefore preventing cell division. However, the low survival effect of docetaxel has prompted researchers to search for novel therapeutic agents. Fucoidan (FUC) is a sulfated polysaccharide derived from brown algae. It has many bioactivities which makes fucoidan a promising anticancer agent. In this study, the potential anti-tumorigenic and preventive effects of fucoidan with or without docetaxel in prostate cancer were investigated by analyzing different cell death modalities. ⋯ According to the findings of this study, FUC inhibited tumor growth temporally and dimensionally, especially in preventive applications. FUC and FUC+DOC combinations in both treatment groups showed anti-tumorigenic effects. The results of this study suggest that fucoidan is a promising anticancer agent against prostate cancer. FUC can be considered as a preventive or treatment agent in prostate cancer therapy with DOC. Further studies are needed to fully elucidate the mechanism of action of fucoidan in metastatic prostate cancer.